Communicating Pharmaceutical Evidence-Based Outcomes

Transcription

1 Save up I N N to O $300 V A When T I V You E Register M E T by H October O D S 18, F 2013 O R Communicating Pharmaceutical Evidence-Based Outcomes D E C E M B E R 3-4, H YAT T AT T H E B E L L E V U E P H I L A D E L P H I A, PA Changing the Value Equation for Payers, Physicians, and Patients Utilizing HEOR and Real-World Data ELITE SPEAKING FACULTY INCLUDES: Michael Christman President, Chief Executive Officer CORIELL INSTITUTE FOR MEDICAL RESEARCH Charlene Keller Fullmer Assistant United States Attorney U.S. ATTORNEY S OFFICE, EASTERN DISTRICT OF PENNSYLVANIA Gregory W. Daniel, PhD, MPH, RPh Managing Director ENGELBERG CENTER FOR HEALTH CARE REFORM THE BROOKINGS INSTITUTION Mark Gibson Director, Center for Evidence-Based Policy OREGON HEALTH & SCIENCES UNIVERSITY SCHOOL OF MEDICINE Rick Mathis, PhD Health Institute BLUECROSS BLUESHIELD OF TENNESSEE Jamie Partridge, PhD, MBA Director, Health Economics and Outcomes Research ABBOTT NUTRITION RESEARCH AND DEVELOPMENT Michael White, PharmD, CSP Director, Clinical Pharmacy Services BLUECROSS BLUESHIELD OF TENNESSEE THIS IS THE ONLY INDUSTRY EVENT TO EXAMINE THE ROLE OF CROSS-FUNCTIONAL TEAMS TO DISSEMINATE OUTCOMES DATA TO KEY STAKEHOLDERS BY: Re-defining the value of pharmaceutical products through HEOR and RWE Cultivating innovative, high-level field teams to educate stakeholders and cultivate customer relationships MEDIA PARTNER: Creating new, cross-functional alliances consisting of medical affairs, commercialization, and product development educate each other and collaborate on outcomes data communication efforts ORGANIZED #EBO13 To Register, please visit Phone: Fax: wcreg@worldcongress.com

2 I N N O V A T I V E M E T H O D S F O R Communicating Pharmaceutical Evidence-Based Outcomes D E C E M B E R 3-4, P H I L A D E L P H I A, P A Changing the Value Equation for Payers, Physicians, and Patients Utilizing HEOR and Real-World Data Dear Colleague, The value in evidence-based medicine is clear the methods to gather and analyze evidence-based data have been made available, and the next step is the practical application of this information to communication strategies. This summit brings together leading experts in communicating evidence-based outcomes and real-world data. Together, we can bridge the gap between product development and commercialization when communicating with customers and stakeholders. This will be a key differential in product success in the future. Our summit features best practices for bringing together medical affairs, product development, and commercialization to create a new alliance that will transform current communication strategies. New methods for reaching payers, prescribers, and patients are evaluated with an emphasis on demonstrating product value and reducing risk. I invite you to join us for this exclusive summit and participate in the thought leading discussions that will propel the pharmaceutical industry forward. I look forward to seeing you in December in Philadelphia! Kind regards, Holly Gately Division Director, Pharmaceutical Events World Congress Who Should Attend Medical Affairs Commercialization Product Development Health Economics Outcomes Research (HEOR) Product Marketing Access Marketing Payer Marketing Communication MARCOM Product Manager Brand Manager Market Development Managed Care Marketing Evidence Solutions WHY YOU SHOULD SPONSOR POSITION your company as a leading solutions and service provider MEET your market SHOWCASE new technology innovations INCREASE brand awareness GENERATE leads and new business DEVELOP new and current client relationships To inquire about Sponsorship and Executive Networking Opportunities, Contact David Capobianco, Vice President, Business Development, World Congress Call or David.Capobianco@worldcongress.com

3 TUESDAY, DECEMBER 3, :30 am 9:00 am Summit Registration and Continental Breakfast 9:00 am 9:45 am OPENING KEYNOTE ADDRESS The New Role of the Manufacturer Strategies to Meet the Challenge of Evolving Market Forces Impacting Access The ACA and developing payment and delivery reforms have shifted the focus of providers and payers to delivering measurably higher quality care at lower cost. In parallel, recent regulatory reforms in the pharmaceutical space have focused on expediting the development of promising therapies to address unmet needs and patient-centered outcomes. These trends are forcing pharmaceutical manufacturers to re-define their strategies and possibly their roles to address these market changes today. This session discusses some of the policy reforms that are affecting the market and provides an understanding of the trends that manufacturers should be responding to to demonstrate value in the context of how products are reimbursed. Understand the payment reforms and other regulatory reforms facing providers, payers, and manufacturers Discuss opportunities for redefining roles of manufacturers and how earlier engagement can ensure products have an appropriate value profile Discuss the FDA Patient-Focused Drug Development program and how it influences patient engagement Gregory W. Daniel, PhD, MPH, RPh Managing Director ENGELBERG CENTER FOR HEALTH CARE REFORM, THE BROOKINGS INSTITUTION Dr. Daniel oversees and provides strategic direction for evidence development including developing practical policy strategies, with broad stake-holder support, for improving US capabilities in the areas of medical product safety surveillance, comparative effectiveness research, and biomedical innovation. 9:45 am 10:15 am Networking and Refreshment Break 10:15 am 11:00 am Re-Defining Value Transform the Positioning of Pharmaceutical Products in the Continuum of Care The definition of value is evolving in the health care industry and the pharmaceutical industry has the opportunity to direct stakeholders viewpoints accordingly. Changing the mindset of what value truly means, pharmaceutical professionals can capitalize on the following initiatives: Transforming stakeholder views to focus on how pharmaceutical products fit in the continuum of care Creating content-rich, comprehendible messages to reach payers, physicians, and patients Leveraging internal business transformations to demonstrate value and commitment to the continuum of care Mark Gibson Director, Center for Evidence-Based Policy OREGON HEALTH & SCIENCE UNIVERSITY SCHOOL OF MEDICINE Mark Gibson is the Director of the Center for Evidence-based Policy. Mark brings to the Center more than two decades of experience as a health policymaker, as both Chief of Staff and as a Policy Advisor for Health and Human Services to Oregon Governor John Kitzhaber. 11:00 am 12:00 pm Reach Your Customers Payer and Pharmacy Perspectives on Value-Based Reimbursement Reimbursement models are undergoing significant change as the health care industry narrows the focus on quality, value, and outcomes. This session discusses the evolving perspective on approval of medical technology and pharmacy products, with a focus on: How health plans are making their approval determinations The ways in which real world data is best presented to payers The impact of PCORI on pharmaceuticals and how/if CER is currently being utilized by health plans Reimbursement methodologies that help to move physicians to high-quality, lower cost care Michael White, PharmD, CSP Director, Clinical Pharmacy Services BLUECROSS BLUESHIELD OF TENNESSEE Dr. White is responsible for all clinical initiatives across the BCBST enterprise and for all aspects of maintaining the clinical integrity of the pharmacy care management programs, utilization management oversight, the pharmacy appeals process, and the specialty pharmacy program. Rick Mathis, PhD Health institute BLUECROSS BLUESHIELD OF TENNESSEE Rick Mathis currently researches health and health policy at BCBST s Health Institute and was formerly their Senior Manager of Medical Policy Research and Development. In that capacity he oversaw the assessment of new and existing medical therapeutics and diagnostics for the plan. 12:00 pm 1:00 pm Networking Luncheon

4 TUESDAY, DECEMBER 3, 2013 (CONTINUED) 1:00 pm 1:45 pm Assemble a Cross-Functional Team to Maximize the Impact of HEOR Data The process of collecting, sorting, and sharing HEOR data is a complex task that must be handled by a team of cross-functional titles to make the best use of time, resources, and knowledge. Learn the step-by-step process for creating a successful internal team. Defining roles incorporating key players to collect, analyze, and distribute real-world data Allocating time to assess cross-functional team needs and resources Merge individual contributions to move communication forward in a complex health care landscape Jamie Partridge, PhD, MBA Director, Health Economics and Outcomes Research ABBOTT NUTRITION RESEARCH & DEVELOPMENT Jamie Partridge, PhD, joined Abbott Nutrition Research and Development as Director of Health Economics and Outcomes Research (HEOR) in April, The focus of her activities centers on HEOR initiatives being developed and expanded in the Therapeutic Nutrition Area, as well as expanding HEOR capacities and influence around the globe. 1:45 pm 2:30 pm The New Face of Pharma Utilizing Comparative Cost Effectiveness to Retain Customers After the Patent Cliff 2:30 pm 3:00 pm The drug patent cliff affects a large number of pharmaceutical companies and their blockbuster products. The next steps are crucial to continued success new methods to retain patients must be developed and time is of the essence. Key objectives to establish a successful product portfolio includes: Incorporating real-world data for product optimization for a diverse portfolio Communicating change and demonstrating value to payers, physicians, and patients Utilizing Comparative Cost Effectiveness to prove the value in expense Robert Freeman, PhD Professor of Pharmacy Administration, Department of Pharmacy Practice and Administration UNIVERSITY OF MARYLAND EASTERN SHORE SCHOOL OF PHARMACY Robert Freeman, PhD, has over 20 years experience in the pharmaceutical industry having served as a leader of public policy and health economics functions for AstraZeneca and Sanofi. Networking and Refreshment Break in the Executive Networking Lounge 3:00 pm 3:45 pm Prepare for the Future of Personalized Patient Care Using Real-World Evidence to Support Product Development and Commercial Teams The market for personalized medicine is on track to more than double by 2015, which marks this as a crucial time prepare for the inclusion of personalized medicine in the continuum of care. Discuss emerging models for generating the Real-World Data needed for communicating personal therapies Utilize communication strategies to position personalized medicine in the context of reducing health care cost and improving quality Michael Christman, PhD President and CEO CORIELL INSTITUTE FOR MEDICAL RESEARCH Michael Christman, PhD, initiated the Coriell Personalized Medicine Collaborative (CPMC ), a research study evaluating the utility of using the knowledge of genetics in medicine. 3:45 pm 4:45 pm Expand the Role of Medical Affairs and Professional Education in Marketing Goals and Ensure Brand Plans Are Effectively Executed Medical Affairs has taken the lead role in professional education and will only continue to grow as the need for additional evidence-based data arises. Key players in med affairs must take a lead role in shifting the pharmaceutical industry to a evidence-based mindset. Explore the steps in expanding the role of medical affairs: Evidence-Based Market conditioning from a Medical Affairs perspective Educating Key Opinion Leaders on product attributes and building relationships Pre-launch preparation for product market positioning and messaging from a scientific standpoint Dom Ricci, MD Pharma Medical Affairs / Market Consulting Dr. Ricci has served the pharmaceutical and biotechnology industries as an integral part of the Medical Affairs Dept. at Shire and Optimer, focusing on an internal scientific and marketing integration approach to advance product awareness and best possible patient care. 4:45 pm 5:45 pm Cocktail Reception in Executive Networking Lounge

5 8:00 am 8:30 am WEDNESDAY, DECEMBER 4, 2013 Registration and Welcome Coffee in the Executive Networking Lounge 8:30 am 9:15 am Developing a Field Communication Team to Effectively Deploy Real-World Evidence The role of the MSL and field representatives is crucial in peer-to-peer collaboration and learning. With the expansion of HEOR data and demand for value-based information, these teams and their responsibilities will expand to accommodate changing educational needs with the following: MSL Training, timing and talent required to meet the evolving HEOR healthcare environment Scientific communication and outcomes data who should the main communicators of this data be? Collaborating to create value for both the healthcare company and healthcare provider Robin Winter-Sperry, MD President and CEO SCIENTIFIC ADVANTAGE Robin Winter-Sperry, MD has developed field medical teams at Novartis and Sanofi-Aventis and has been involved in over twenty-four product launches including products such as Lamisil, Ambien, Diovan and Vesicare. 9:15 am 10:15 am Data Transparency How Much is Too Much for Non-Compliance? Comprehensive outcomes data is needed to demonstrate value and receive reimbursement, however; any off-label information used to promote a product is punishable by fines and even the removal of corporate executives. Protect information sharing practices with an understanding of the following: FDAMA114 and its implications in relation to evidence-based marketing strategies Techniques to remain compliant while providing essential information to customers and stakeholders Utilizing off-label information in real-world data collections Charlene Keller Fullmer Assistant United States Attorney U.S. ATTORNEY S OFFICE EASTERN DISTRICT OF PENNSYLVANIA As an Assistant US Attorney, Charlene Keller Fullmer prosecutes health care and affirmative fraud matters. She served as part of the prosecution team that investigated and resolved allegations of off-label promotion and kickbacks by Pfizer, Inc. and its employees. The $2.3 billion civil and criminal resolution was at the time the largest health care fraud settlement in the history of the Department of Justice. 10:15 am 11:00 am Rethinking ROI How Evidence-Based Communication Contributes to Your Bottom Line Changes in the foundation of product commercialization will inevitably lead to a change in your return on investment. Tightened budgets and new regulations require strategic planning and a new focus on the potential scenarios for ROI. Considerations in this process include: Navigating changes in product development, commercialization, and profitability Understanding the moving pieces of the Affordable Care Act and how these initiatives affect processes and costs of commercialization Creating a sustainable ROI model to move forward without shrinking profit margins Jayant Joshi Chief Operating Officer IRIS INTERACTIVE CORPORATION Mr. Joshi has significant experience in building brands through innovation in consumer packaged goods and prescription pharmaceuticals industries. He has worked extensively with cross-functional teams including clinical operations, medical affairs, regulatory, health economics and market access professionals. 11:00 am Close of Conference

6 What Our Attendees Say About Our Summits: Program provided many insights and tools in providing improvements in medication adherence, which at the end of the day will improve the health outcome of the patients we provide services to every day. Albert Garcia RPh, MHL, President, Navarro Discount Pharmacy Excellent content that creates strong learning and networking environment. Mark Goldman, Bus. Dev. Lead, Philips Healthcare Home Monitoring Great range of speakers and topics with amazing Interventions and technologies. It s great to see that all parts of the healthcare system come together to fix this issue of medical non-adherence. Rmannon Quirk, Engineer, Biogen Idec The topics were very relevant and the content covered many aspects from how people behave to how to predict and best engage all providers in the care model. Julie Lambert, Sr. Director, Prime Therapeutics WHY YOU SHOULD SPONSOR POSITION your company as a leading solutions and service provider MEET your market SHOWCASE new technology innovations INCREASE brand awareness GENERATE leads and new business DEVELOP new and current client relationships Benefit from one-on-one meetings, corporate branding and relationship building by participating as an active corporate supporter and sponsor. World Congress offers various levels of support and sponsorship opportunities at the event including but not limited to: Platinum, Gold, and Silver Event Sponsorship Educational Sponsorship Tabletop Exhibits Executive Networking Opportunities Online Advertising / Sponsorships To inquire about Sponsorship and Executive Networking Opportunities, Contact David Capobianco, Vice President, Business Development, World Congress Call or David.Capobianco@worldcongress.com

7 I N N O V A T I V E M E T H O D S F O R Communicating Pharmaceutical Evidence-Based Outcomes D E C E M B E R 3-4, P H I L A D E L P H I A Upcoming World Congress Pharmaceutical Events World Congress Pharmaceutical is the leading provider of global market-driven, educational conferences for the pharmaceutical industry. Visionary, global perspectives from senior thought leaders set our conferences apart whether the event is focusing on regulatory and compliance challenges, the latest sales and marketing strategies, or opportunities in emerging markets, our meetings provide actionable ideas and real-world strategies you can bring back to your organization. To be considered for our speaking faculty please submit abstracts to Holly.Gately@worldcongress.com., P A Changing the Value Equation for Payers, Physicians, and Patients Utilizing HEOR and Real-World Data The 2nd Annual Global Pharmaceutical and Medical Meetings Summit February 3 5, 2014 Loews Philadelphia Hotel Philadelphia, PA Where Pharmaceutical, Biotech, Medical Device and Health Care Senior Meeting Professionals Convene to Innovate, Educate and Network 2nd Annual World Congress Summit to Improve ADHERENCE and Enhance PATIENT ENGAGEMENT Collaboration on Effective Interventions, Coordination, Quality, and Measurable Outcomes March 10-11, 2014 Philadelphia, PA THE WORLD CONGRESS PHARMACEUTICAL DIVISION IS PROUD TO PRESENT THE 2ND ANNUAL Thought Leader Engagement, the Role of MEDICAL AFFAIRS and MEDICAL SCIENCE LIAISONS in the Era of Healthcare Reform ESTABLISHING A CULTURE OF KNOWLEDGE AND VALUE: INSIGHTS FROM KOLs AND INTERNAL STAKEHOLDERS May 20-21, 2014 Philadelphia, PA

8 TO REGISTER, please visit Phone: Fax: Registration Fee: PHARMA / BIOTECH Register By 10/18/2013 Register By 12/03/2013 Conference $ $ HOSPITAL & HEALTH SYSTEMS Conference $ $ HEALTH PLANS Conference $ $ NON-PROFIT/ASSOCIATIONS Conference $ $ SOLUTION PROVIDERS Conference $ $ Fee for the conference includes welcome coffee, lunch, reception, refreshments, and web-based conference documentation available pre- and post-event through a password protected web-site. Please make checks (in U.S. funds drawn on a U.S. bank) payable to WC Research, Inc. (No personal checks accepted. Verification may be required.) * Please note Vendor Rates are to attend the event only. If you are interested in Sponsorship & Exhibiting Opportunities please David.Capobianco@worldcongress.com. Please contact us should you have any special needs. Team Registration: Your organization may send 1 executive FREE for every 3 delegates registered. All registrations must be made at the same time to qualify. Substitution & Cancellation: Your registration may be transferred to a member of your organization up to 24 hours in advance of the conference. Cancellations received in writing on or before 30 days prior to the start of the event will be refunded, less a $395 administrative charge. No refunds will be made after this date; however, the registration fee less the $395 administrative charge can be credited to another World Congress conference if you register within 6 months from the date of this conference. In case of conference cancellation, World Congress liability is limited to refund of the conference registration fee only. World Congress reserves the right to alter this program without prior notice. Satisfaction Guaranteed: World Congress stands behind the quality of its conferences. If you are not satisfied with the quality of the conference, a credit will be awarded towards a comparable World Congress conference of your choice. Venue: Hyatt at the Bellevue 200 South Broad Street, Philadelphia, PA Tel: (215) Room Rate: $179 Cut-off Date: 11/12/13 Register Now! WEBSITE WorldCongress.com /PharmaEvidence Best Value wcreg@worldcongress.com I N N O V A T I V E M E T H O D S F O R Communicating Pharmaceutical Evidence-Based Outcomes DECEMBER 3-4, 2013 HYATT AT THE BELLEVUE PHILADELPHIA, PA Changing the Value Equation for Payers, Physicians, and Patients Utilizing HEOR and Real-World Data Top Reasons to Attend: Hear from top pharmaceutical executives about cross-functional evidence-based communication strategies Discover the new roles and team functions of Health Outcomes Liaisons (HOLs) Explore new technologies for communicating evidence-based information to key stakeholders and customers, including ipad applications Learn how to develop a product lifecycle communication plan Address the concerns and demands of your customers and stakeholders payers and ACOs in the context of which your product is reimbursed Position new and mature products to fit the continuum of care and reduce risk for physicians, payers, and patients Understand the implications of data transparency and which information can lead to non-compliance TO REGISTER, please visit Phone: Fax: wcreg@worldcongress.com